# Stem cells weekly update — no public article change Date: 2026-08-03 Site: Managing Expectations / Health Primary article: `/blog/articles/stem-cells-evidence-costs-risks-global-guide.html` Launch source note: `/research/health/stem-cells-evidence-costs-risks-source-note-2026-06-20.md` Previous weekly note: `/research/health/stem-cells-weekly-update-2026-07-27.md` Raw local check file: `/tmp/stem_weekly_check_2026-08-03.json` during this cron run ## Bottom line No public article change is recommended this week. The weekly scan found continuing activity in regulated transplant medicine, early-phase regenerative trials, orthopedic/osteoarthritis studies, Parkinson's cell-therapy trials, MSC/exosome reviews, and global advanced-therapy regulation, but no new FDA/Health Canada/ISSCR/AAOS policy change, safety warning, approval-list change, or high-quality clinical evidence that materially changes the Managing Expectations stem-cell report. The existing article frame remains current: established stem-cell medicine is mostly narrow and specialist-led; approved cellular/gene products are indication-specific; frontier iPSC/MSC/exosome uses remain promising or investigational unless tied to a specific approved product/indication; and commercial clinic/testimonial claims should not be treated as proof. ## Sources checked this run ### United States — FDA / NIH / NCI / ClinicalTrials.gov - FDA, **Important Patient and Consumer Information About Regenerative Medicine Therapies** URL: https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies Retrieval: HTTP 200 by direct scripted fetch. Metadata observed: `dateModified Mon, 04/08/2024 - 13:00`. Finding: No new consumer-warning change identified. FDA's warning still covers unapproved stem cells, stromal vascular fraction, umbilical cord/cord-blood stem cells, Wharton's jelly, ortho-biologics and exosomes, and reports of serious harms including blindness, tumor formation and infections. - FDA, **Approved Cellular and Gene Therapy Products** URL: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products Retrieval: HTTP 200. Metadata observed: `dateModified Wed, 07/01/2026 - 06:00`. Finding: No newer FDA approved-product-list change was identified beyond the July 1 list update already reflected in the public article's July 6 callout. The list remains product- and indication-specific. - FDA, **Regenerative Medicine Advanced Therapy Designation** URL: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenerative-medicine-advanced-therapy-designation Retrieval: HTTP 200. Metadata observed: `dateModified Tue, 11/04/2025 - 16:20`. Finding: No article change. RMAT is a development/regulatory designation, not proof that a marketed stem-cell clinic product is approved. - NIH, **Stem Cell Basics** URL attempted: https://stemcells.nih.gov/info/basics/stc-basics/ Retrieval: HTTP 403 in this cron environment. Finding: No article change was made from the blocked source. Prior source notes preserve the NIH baseline definitions and distinctions among pluripotent, adult/somatic and blood-forming stem cells. - NCI, **Stem Cell and Bone Marrow Transplants for Cancer** URL: https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant Retrieval: HTTP 200. Finding: NCI's specialist-transplant framing remains consistent with the article: blood/bone-marrow transplant can be established medicine for selected cancers and blood/immune disorders, but it is high-risk medical treatment rather than casual wellness therapy. - ClinicalTrials.gov v2 API, broad scan sorted by last update for stem-cell therapy, mesenchymal stromal cells, induced pluripotent stem cells, exosome therapy, HSCT, Parkinson's, diabetes, spinal-cord injury and arthritis. Retrieval: HTTP 200. Notable current registry activity: CARTISTEM phase 3 knee cartilage/osteoarthritis listing (NCT07339111; recruiting; updated 2026-07-31); Parkinson's cell-therapy listings including UX-DA003 (NCT07733349; phase 1/2; not yet recruiting; updated 2026-07-29) and RNDP-001 (NCT07106021; phase 1/2; active not recruiting; updated 2026-07-27); early spinal-cord injury listing NeuroRise / intrathecal CE-1 (NCT07739043; early phase 1; not yet recruiting; updated 2026-07-31); and multiple HSCT/CAR-T supportive-care/transplant studies. Finding: Trial-list activity is worth tracking but is not proof of clinical benefit or authorization for cash-pay commercial use. ### Canada — Health Canada - Health Canada, **Unauthorized cell therapy warning** URL: https://recalls-rappels.canada.ca/en/alert-recall/health-canada-advising-canadians-about-potential-health-risks-associated-unauthorized Retrieval: HTTP 200. Metadata observed: 2019-05-15. Finding: No new Health Canada warning was identified. The 2019 warning remains the key Canadian consumer-safety anchor. - Health Canada, **Policy Position Paper — Autologous Cell Therapy Products** URL: https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/cell-therapy-policy.html Retrieval: HTTP 200. Metadata observed: 2020-01-17. Finding: No article change. The page continues to support the article's point that autologous cell products can still raise safety/regulatory issues; using a patient's own cells does not automatically make a therapy low-risk or outside oversight. ### Guidelines / professional societies - ISSCR, **Guidelines for Stem Cell Research and Clinical Translation** URL: https://www.isscr.org/guidelines Retrieval: HTTP 200. Finding: No new guideline change requiring a public article update. The standing principles remain oversight, transparency, valid evidence and responsible clinical translation. - ISSCR, **Policy** URL: https://www.isscr.org/policy Retrieval: HTTP 200. Finding: No new policy item surfaced that changes the article. - AAOS/OrthoInfo, **Use of Stem Cells in Orthopaedics** URL: https://orthoinfo.aaos.org/en/treatment/use-of-stem-cells-in-orthopaedics/ redirected to https://www.orthoinfo.org/treatment/use-of-stem-cells-in-orthopaedics/ Retrieval: HTTP 200. Finding: AAOS caution remains consistent with the article: orthopedic applications are still being tested; symptom reports do not prove cartilage/tendon/spine regeneration or long-term disease modification. ### Global regulatory scan - EMA, **Advanced therapy medicinal products: Overview** URL: https://www.ema.europa.eu/en/human-regulatory-overview/advanced-therapy-medicinal-products-overview Retrieval: HTTP 200. Metadata observed: 2023-11-08. Finding: No new EU/EMA change was identified. EMA continues to treat ATMPs as regulated medicines. - UK MHRA, **Advanced therapy medicinal products: regulation and licensing in UK** URL: https://www.gov.uk/guidance/advanced-therapy-medicinal-products-regulation-and-licensing Retrieval: HTTP 200, redirected to the current GOV.UK page. Metadata observed: 2025-03-06. Finding: No article change; UK ATMP/regenerative products remain regulated under medicines/tissues frameworks. - Japan PMDA/MHLW, **Strategy of SAKIGAKE by MHLW** URL: https://www.pmda.go.jp/english/review-services/reviews/advanced-efforts/0001.html Retrieval: HTTP 200. Finding: No new Japan policy event was found that changes the article. Japan remains a distinctive accelerated-pathway jurisdiction for innovative medical/regenerative products, but approval status still needs product-specific verification. - Singapore HSA, **Cell, Tissue and Gene Therapy Products** URL: https://www.hsa.gov.sg/ctgtp/ Retrieval: HTTP 200. Finding: Confirms a regulated CTGTP category; no new article-changing policy event surfaced. - Australia TGA, **Biologicals** URL: https://www.tga.gov.au/products/biologicals Retrieval: HTTP 200. Finding: Useful global-regulatory anchor; no new public article change. - Australia TGA, older autologous human cells/tissue guidance path URL attempted: https://www.tga.gov.au/resources/resource/guidance/autologous-human-cells-and-tissue-products Retrieval: HTTP 404. Finding: No article change made from this unavailable page. ### Peer-reviewed / PubMed scan - PubMed ESearch/EFetch, publication-date scan from 2026-07-27 to 2026-08-03 for clinical cell therapy, mesenchymal stromal/stem cells, iPSC, exosomes, HSCT outcomes/safety, systematic reviews and frontier indications. Retrieval: HTTP 200. PubMed returned 12 items in each tracked query bucket. Some PubMed records returned future journal issue dates while appearing in the current indexed-results response; those were treated as source leads, not as article-changing facts by date alone. - **Efficacy and Safety of Intracoronary Mesenchymal Stem Cell Administration in ST-Segment Elevation Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials**. PMID: 42499248. DOI: 10.1111/cts.70682. Finding: Eight RCTs / 796 patients identified; modest left-ventricular-function signal, no reduction in clinical events, limited safety data, and larger longer trials still needed. Evidence label: **promising/under study** for cardiac repair; not a general clinic-marketing proof point. - **Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial**. PMID: 42532067. DOI: 10.1016/S2352-3026(26)00167-5. Finding: Specialist HSCT complication-prevention literature; relevant to transplant medicine, but it does not change consumer-facing regenerative-clinic guidance. Evidence label: **specialist transplant medicine**, not broad commercial stem-cell therapy. - **High-intensity immunosuppression versus modern standard care in poor-prognosis diffuse cutaneous systemic sclerosis: A propensity-matched study**. PMID: 42361515. DOI: 10.1016/j.jaut.2026.103594. Finding: Supports that autologous HSCT may be used in selected severe autoimmune contexts at specialist centers, with significant risk/selection issues. This is already represented in the article. Evidence label: **selected specialist use**, not casual immune-reset/wellness infusion. - **A comparative analysis of MSCs and their exosomes in osteoarthritis therapy: complementary roles and clinical translation**. PMID: 42157532. DOI: 10.1080/08923973.2026.2673950. Finding: Review-level source saying symptomatic relief is seen in trials but structural cartilage-regeneration evidence is inconsistent; exosome clinical confirmation and standardization remain limited. Evidence label: **investigational/uncertain durability**, consistent with existing orthopedic caution. - **A Systematic Review on Disease-Modifying Therapies in Parkinsonian Disorders**. PMID: 42104724. DOI: 10.1002/cpt.70315. Finding: Stem-cell therapies remain largely investigational in Parkinsonian disorders, with no approved disease-modifying therapy for Parkinsonian disorders according to the abstract. Evidence label: **investigational**, consistent with existing neurologic-claim caution. - **Efficacy and Safety of Mesenchymal Stem Cell Therapy for Alzheimer's Disease: A Systematic Review and Meta-Analysis**. PMID: 42483783. DOI: 10.1177/15473287261468404. Finding: Already included in the July 27 article update. It continues to reinforce that dementia claims remain insufficiently proven. ## What changed - A dated no-change source note was created for audit continuity. - New registry and PubMed leads were captured for future monitoring. - No public article, Health page or pricing/regulatory table change is recommended this week. ## What did not change - FDA's consumer warning remains the main U.S. safety anchor for unapproved regenerative products. - FDA's approved cellular/gene therapy list remains current at July 1, 2026 in this run and remains narrow/product-specific. - Health Canada's warning and autologous-cell policy position remain unchanged as public-facing anchors. - ISSCR and AAOS cautionary framing remains unchanged. - ClinicalTrials.gov updates, early-phase trial listings, review articles and specialist-transplant studies do not justify clinic endorsement, dosing/protocol guidance, medical-tourism encouragement or cure framing. ## Suggested article edits None this week. Preserve the existing July 27 callout and article text. Reconsider a public update only if there is a new regulator warning/approval, a major guideline change, a high-quality human trial result that shifts evidence labels, or a credible public-safety/adverse-event development. ## Medical/editorial boundary This note is source tracking only. It is not medical advice, diagnosis, treatment guidance, dosing guidance, trial recruitment advice, clinic endorsement, or encouragement to travel for treatment.